U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H32ClN5O2
Molecular Weight 470.007
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEFAZODONE

SMILES

CCC1=NN(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)C(=O)N1CCOC4=CC=CC=C4

InChI

InChIKey=VRBKIVRKKCLPHA-UHFFFAOYSA-N
InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3

HIDE SMILES / InChI

Molecular Formula C25H32ClN5O2
Molecular Weight 470.007
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/nefazodone.html

Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. Within the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.

CNS Activity

Curator's Comment: antidepressant

Originator

Curator's Comment: # Bristol-Myers Squibb

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.8 nM [Ki]
290.0 nM [Ki]
5.5 nM [Ki]
84.0 nM [Ki]
52.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NEFAZODONE HYDROCHLORIDE

Approved Use

Nefazodone hydrochloride tablets are indicated for the treatment of depression. When deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with Nefazodone hydrochloride treatment. In many cases, this would lead to the conclusion that other drugs should be tried first.

Launch Date

1.06358401E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1588 ng/mL
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
880 μg/L
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
415 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
276 μg/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6378 ng × h/mL
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3213 μg × h/L
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1220 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
787 μg × h/L
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.2 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.7 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NEFAZODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: hepatic cirrhosis
Age Group: adult
Sex: unknown
Population Size: 12
Sources:
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting
Sources:
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: renal impairment
Age Group: adult
Sex: unknown
Population Size: 12
Sources:
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting
Sources:
430 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 430 mg, 1 times / day
Route: oral
Route: steady
Dose: 430 mg, 1 times / day
Sources:
unhealthy, adult
n = 19
Health Status: unhealthy
Condition: Posttraumatic stress disorder
Age Group: adult
Sex: M
Population Size: 19
Sources:
Other AEs: Headaches, Dry mouth...
Other AEs:
Headaches (53%)
Dry mouth (42%)
Diarrhea (42%)
Sources:
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Other AEs: Dry mouth, Nausea...
Other AEs:
Dry mouth (25%)
Nausea (22%)
Dizziness (17%)
Constipation (14%)
Asthenia (11%)
Light headedness (10%)
Blurred vision (9%)
Confusion (7%)
Abnormal vision (7%)
Sources: Page: Table 1
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 2
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 2
Other AEs: Somnolence...
Other AEs:
Somnolence (25%)
Sources: Page: Table 2
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 565
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 565
Sources: Page: Table 1
Disc. AE: Nausea, Headache...
AEs leading to
discontinuation/dose reduction:
Nausea (3.5%)
Headache (2.9%)
Dizziness (1.9%)
Somnolence (1.5%)
Insomnia (1.5%)
Asthenia (1.3%)
Agitation (1.2%)
Sources: Page: Table 1
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
healthy, elderly
n = 12
Health Status: healthy
Age Group: elderly
Sex: unknown
Population Size: 12
Sources:
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting
Sources:
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
healthy, younger
n = 12
Health Status: healthy
Age Group: younger
Sex: unknown
Population Size: 12
Sources:
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting
Sources:
AEs

AEs

AESignificanceDosePopulation
Nausea and vomiting
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: hepatic cirrhosis
Age Group: adult
Sex: unknown
Population Size: 12
Sources:
Nausea and vomiting
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy, adult
n = 12
Health Status: unhealthy
Condition: renal impairment
Age Group: adult
Sex: unknown
Population Size: 12
Sources:
Diarrhea 42%
430 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 430 mg, 1 times / day
Route: oral
Route: steady
Dose: 430 mg, 1 times / day
Sources:
unhealthy, adult
n = 19
Health Status: unhealthy
Condition: Posttraumatic stress disorder
Age Group: adult
Sex: M
Population Size: 19
Sources:
Dry mouth 42%
430 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 430 mg, 1 times / day
Route: oral
Route: steady
Dose: 430 mg, 1 times / day
Sources:
unhealthy, adult
n = 19
Health Status: unhealthy
Condition: Posttraumatic stress disorder
Age Group: adult
Sex: M
Population Size: 19
Sources:
Headaches 53%
430 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 430 mg, 1 times / day
Route: oral
Route: steady
Dose: 430 mg, 1 times / day
Sources:
unhealthy, adult
n = 19
Health Status: unhealthy
Condition: Posttraumatic stress disorder
Age Group: adult
Sex: M
Population Size: 19
Sources:
Light headedness 10%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Asthenia 11%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Constipation 14%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Dizziness 17%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Nausea 22%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Dry mouth 25%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Abnormal vision 7%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Confusion 7%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Blurred vision 9%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 1
Somnolence 25%
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 2
unhealthy, adult
n = 394
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 394
Sources: Page: Table 2
Agitation 1.2%
Disc. AE
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 565
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 565
Sources: Page: Table 1
Asthenia 1.3%
Disc. AE
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 565
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 565
Sources: Page: Table 1
Insomnia 1.5%
Disc. AE
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 565
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 565
Sources: Page: Table 1
Somnolence 1.5%
Disc. AE
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 565
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 565
Sources: Page: Table 1
Dizziness 1.9%
Disc. AE
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 565
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 565
Sources: Page: Table 1
Headache 2.9%
Disc. AE
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 565
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 565
Sources: Page: Table 1
Nausea 3.5%
Disc. AE
600 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources: Page: Table 1
unhealthy, adult
n = 565
Health Status: unhealthy
Condition: major depression
Age Group: adult
Sex: unknown
Population Size: 565
Sources: Page: Table 1
Nausea and vomiting
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
healthy, elderly
n = 12
Health Status: healthy
Age Group: elderly
Sex: unknown
Population Size: 12
Sources:
Nausea and vomiting
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
healthy, younger
n = 12
Health Status: healthy
Age Group: younger
Sex: unknown
Population Size: 12
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Depression, sleep physiology, and antidepressant drugs.
2001
Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues.
2001
Algorithm for the treatment of chronic depression.
2001
Acute and maintenance treatment of chronic depression.
2001
Bupropion and drug-induced parkinsonism.
2001 Aug
[Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
2001 Aug
Autonomic neurocardiac function in patients with major depression and effects of antidepressive treatment with nefazodone.
2001 Feb
Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes.
2001 Feb
Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.
2001 Jan
Antidepressants as analgesics: a review of randomized controlled trials.
2001 Jan
Response to nefazodone in a depressed patient with end-stage renal disease.
2001 Jan-Feb
Open trial of nefazodone for combat veterans with posttraumatic stress disorder.
2001 Jul
The 'dalhousie serotonin cocktail' for treatment-resistant major depressive disorder.
2001 Jun
Depression and anxiety disorders.
2001 Jun
Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone.
2001 Jun
Which depressed patients respond to nefazodone and when?
2001 Mar
Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.
2001 May
Increase in plasma levels of clozapine and norclozapine after administration of nefazodone.
2001 May
Nefazodone for chronic daily headache prophylaxis: an open-label study.
2001 May
Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis.
2001 May
Possible interaction of zopiclone and nefazodone.
2001 Nov
Pharmacotherapy for post-traumatic stress disorder: a comprehensive review.
2001 Oct
[Pharmacotherapeutical approaches to insomnia patients with cardiac diseases and after heart transplantation].
2001 Oct
A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment.
2001 Sep
Clinically significant drug interactions with antidepressants in the elderly.
2002
Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.
2002
Overview of psychiatric disorders and the role of newer antidepressants.
2002
Pharmacology of antidepressants: focus on nefazodone.
2002
Nefazodone and liver damage.
2002 Aug
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression.
2002 Jun
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
2002 May
Hepatic adverse reactions associated with nefazodone.
2002 May
Antidepressant-induced sexual dysfunction.
2002 Oct
[Pharmacological justification for the use of new antidepressant drugs].
2002 Sep
Rhabdomyolysis with simvastatin and nefazodone.
2002 Sep
Enhanced resolution triple-quadrupole mass spectrometry for fast quantitative bioanalysis using liquid chromatography/tandem mass spectrometry: investigations of parameters that affect ruggedness.
2003
Patents

Sample Use Guides

Initial dose: 200 mg orally per day in two divided doses Maintenance dose: 300 to 600 mg orally per day
Route of Administration: Oral
In vitro biliary excretion of micafungin in humans and rats was reduced by 75% in the presence of the bile salt export pump (BSEP) inhibitor nefazodone (25 uM)
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:55:47 UTC 2023
Edited
by admin
on Wed Jul 05 23:55:47 UTC 2023
Record UNII
59H4FCV1TF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NEFAZODONE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
nefazodone [INN]
Common Name English
1-(3-(4-(M-CHLOROPHENYL)-1-PIPERAZINYL)PROPYL)-3-ETHYL-4-(2-PHENOXYETHYL)-.DELTA.(SUP 2)-1,2,4-TRIAZOLIN-5-ONE
Common Name English
NEFAZODONE [VANDF]
Common Name English
3H-1,2,4-TRIAZOL-3-ONE, 2-(3-(4-(3-CHLOROPHENYL)-1-PIPERAZINYL))PROPYL)-5-ETHYL-2,4-DIHYDRO-4-(2-PHENOXYETHYL)-
Common Name English
NEFAZODONE [MI]
Common Name English
Nefazodone [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
WHO-ATC N06AX06
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
NDF-RT N0000175696
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
WHO-VATC QN06AX06
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
LIVERTOX NBK548179
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
Code System Code Type Description
DRUG BANK
DB01149
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
EPA CompTox
DTXSID2023357
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
IUPHAR
7247
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
RXCUI
31565
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY RxNorm
FDA UNII
59H4FCV1TF
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
DAILYMED
59H4FCV1TF
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
MERCK INDEX
M7793
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY Merck Index
CAS
83366-66-9
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
DRUG CENTRAL
1890
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
SMS_ID
100000084127
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
EVMPD
SUB09180MIG
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
MESH
C051752
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
LACTMED
Nefazodone
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
PUBCHEM
4449
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
ChEMBL
CHEMBL623
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
NCI_THESAURUS
C61859
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
WIKIPEDIA
Nefazodone
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
INN
5432
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
CHEBI
7494
Created by admin on Wed Jul 05 23:55:47 UTC 2023 , Edited by admin on Wed Jul 05 23:55:47 UTC 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INHIBITOR
POTENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC